Parathyroid Hormone Mediates Bone Growth through the Regulation of Osteoblast Proliferation and Differentiation

PTH (1–34) is the only FDA-approved anabolic agent for osteoporosis treatment in the U.S., but its mechanisms are not completely understood. This study investigated PTH effects on osteogenic cells at various stages of differentiation and proliferation using an engineered bone growth model in vivo. O...

Descrición completa

Gardado en:
Detalles Bibliográficos
Main Authors: Pettway, Glenda J., Meganck, Jeffrey A., Koh, Amy J., Keller, Evan T., Goldstein, Steven A., McCauley, Laurie K.
Formato: Artigo
Idioma:Inglês
Publicado: 2007
Assuntos:
Article
Acceso en liña:https://ncbi.nlm.nih.gov/pmc/articles/PMC2677418/
https://ncbi.nlm.nih.gov/pubmed/18234576
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.bone.2007.11.017
Tags: Engadir etiqueta
Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!

Títulos similares